ArticleRMD open2026
Relapse risk of lupus-related serositis according to immunosuppressive therapy: a national real-world study.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManagement of systemic lupus erythematosus (SLE) is largely guided by organ involvement. Serositis affects up to 46% of patients, yet its treatment is mainly empirical and extrapolated from other manifestations, and long-term outcome data remain limited. We aimed to evaluate short-term response to anti-inflammatory therapy and to examine associations between immunosuppressive treatments and serositis relapse.
methodsWe conducted a multicentre retrospective real-world study in patients with SLE with pericarditis and/or pleuritis, identified through a nationwide call for case reporting. Initial response was defined as symptom and sign resolution at early reassessment. Relapse was defined as recurrence requiring treatment intensification ≥3 months after the index flare. Relapse-free survival was described by Kaplan-Meier methods and analysed as recurrent events using a Prentice-Williams-Peterson gap-time Cox model adjusted for prespecified confounders.
resultsOne hundred patients contributed 180 serositis episodes (161 pericarditis, 51 pleuritis, associated in 32 cases) over a mean follow-up of 91 months; 46% experienced ≥1 relapse. Overall, 108/124 (87.1%) of evaluable episodes responded to initial anti-inflammatory therapy, with no significant difference between corticosteroid-based and aspirin/colchicine regimens. Corticosteroid use was not associated with increased relapse risk (46.0% vs 46.2%, p=0.98). Conventional immunosuppressants (methotrexate, azathioprine, mycophenolate mofetil) were not associated with reduced relapse risk, whereas belimumab was associated with lower relapse risk (HR=0.34, 95% CI 0.14 to 0.84; p=0.019).
conclusionLupus-related serositis is frequent and highly relapsing. In this national cohort, belimumab-but not conventional immunosuppressants-was associated with reduced serositis recurrence, supporting its further evaluation in lupus serositis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.